Nicole Maronian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nicole Maronian has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Akina Tamaki
Case Western Reserve University School of Medicine Cleveland Ohio USA
3 shared publicationsClaudia I. Cabrera
Case Western Reserve University School of Medicine Cleveland Ohio USA
3 shared publications- Claudia I. Cabrera
Department of Otolaryngology‐Head and Neck Surgery University Hospitals Cleveland Medical Center Cleveland Ohio U.S.A.
3 shared publications Nicole Fowler
Case Western Reserve University School of Medicine Cleveland Ohio USA
2 shared publications- Akina Tamaki
Case Western Reserve University School of Medicine Cleveland Ohio USA
1 shared publication Alexis Nahra
Department of Speech‐Language Pathology University Hospitals Cleveland Medical Center Cleveland Ohio USA
1 shared publication
Latest Publications
- 18 November 2025
- Published by Wiley in The Laryngoscope
- Vol. 136 (4) , 1770-1779
Total Laryngectomy Length of Stay Association With Diagnosis Related Group Classification
Objective: With increased nationwide emphasis on high‐value care and cost reduction, more attention has been paid to postoperative outcomes. In this study, we examined if diagnosis related group (DRG) classifications could be used to predict total laryngectomy (TL) length of stay (LOS) which could help with determining areas for improved resource allocation. Methods: This is a retrospective study at a single tertiary academic center of TL patients between January 2013 and December 2020. For each DRG, we compared the primary outcome of LOS and secondarily examined perioperative outcomes, including complications and readmissions. We used Kruskal‐Wallis tests to assess perioperative outcome and LOS differences among DRGs' correlation. Furthermore, we used public data to determine annual geometric means LOS (GMLOS) for TLs and compared this to institutional LOS. Results: The 211 patients were included. Patients with more severe DRG classification had greater LOS ( p = 0.004). Fistula complications occurred at higher rates in more severe DRG classification, with major complication or comorbidity (MCC) at 25.0%, CC at 16.9%, and without complication or comorbidity (CC)/MCC at 3.1%, p = 0.02. The 30‐day readmission was more common in MCC (26%) compared to CC (8.4%) or without CC/MCC (9.4%), p < 0.01. We found higher GMLOS compared to institutional LOS for TLs. Conclusion: TL patients with CC and MCC have longer LOS than those without CC/MCC, as well as higher fistula and readmission rates. DRGs can be used to identify areas to improve resource allocation for patients that may have poorer post‐TL outcomes. Level of Evidence: 3
- 18 November 2025
- Published by Wiley in The Laryngoscope
- Vol. 136 (4) , 1770-1779
Total Laryngectomy Length of Stay Association With Diagnosis Related Group Classification
Objective: With increased nationwide emphasis on high‐value care and cost reduction, more attention has been paid to postoperative outcomes. In this study, we examined if diagnosis related group (DRG) classifications could be used to predict total laryngectomy (TL) length of stay (LOS) which could help with determining areas for improved resource allocation. Methods: This is a retrospective study at a single tertiary academic center of TL patients between January 2013 and December 2020. For each DRG, we compared the primary outcome of LOS and secondarily examined perioperative outcomes, including complications and readmissions. We used Kruskal‐Wallis tests to assess perioperative outcome and LOS differences among DRGs' correlation. Furthermore, we used public data to determine annual geometric means LOS (GMLOS) for TLs and compared this to institutional LOS. Results: The 211 patients were included. Patients with more severe DRG classification had greater LOS ( p = 0.004). Fistula complications occurred at higher rates in more severe DRG classification, with major complication or comorbidity (MCC) at 25.0%, CC at 16.9%, and without complication or comorbidity (CC)/MCC at 3.1%, p = 0.02. The 30‐day readmission was more common in MCC (26%) compared to CC (8.4%) or without CC/MCC (9.4%), p < 0.01. We found higher GMLOS compared to institutional LOS for TLs. Conclusion: TL patients with CC and MCC have longer LOS than those without CC/MCC, as well as higher fistula and readmission rates. DRGs can be used to identify areas to improve resource allocation for patients that may have poorer post‐TL outcomes. Level of Evidence: 3
- 29 August 2024
- Published by Wiley in The Laryngoscope
- Vol. 135 (1) , 270-276
Mucosal Injection of the Silicon Phthalocyanine Pc 4 in a Rabbit Model—A Pilot Study
Objective: The silicon phthalocyanine Pc 4 is a photosensitizing agent previously shown to be a promising treatment for cutaneous neoplasms using photodynamic therapy (PDT). Based on prior preclinical studies, we believe Pc 4‐PDT has potential as a targeted treatment of human recurrent respiratory papillomatosis or laryngeal leukoplakia by direct injection into mucosal surfaces.Methods: This was a proof‐of‐concept pilot study assessing direct mucosal injection of Pc 4 into buccal and vocal fold mucosae in a rabbit model. Five New Zealand white rabbits underwent tattooing of bilateral buccal mucosae to delineate injection sites, followed by submucosal injections of control and Pc 4 solutions. Rabbits were monitored for post‐injection tolerance. Punch biopsies were obtained from injected mucosa and assessed histopathologically. Once the buccal mucosa was found to be tolerant, vocal folds of three rabbits were injected. The rabbits were then sacrificed, and laryngeal tissue was assessed histopathologically.Results: All rabbits tolerated injection of Pc 4 and control solutions into buccal mucosa with no evidence of gross visual inflammatory changes and no changes in behavior or masticatory function. Histopathologic analysis of Pc 4 injected buccal and control mucosal tissue revealed mild focal histological changes and no stigmata of diffuse inflammatory reactions. The histopathologic analysis of Pc 4 injected into laryngeal tissue revealed similar findings with addition of mild eosinophilia in one sample.Conclusion: Direct mucosal injection of Pc 4 in rabbit buccal and vocal fold mucosae appears to be well tolerated with no gross inflammatory changes, and only mild histopathologic inflammatory changes observed.Level of Evidence: NA Laryngoscope, 2024
- 29 August 2024
- Published by Wiley in The Laryngoscope
- Vol. 135 (1) , 270-276
Mucosal Injection of the Silicon Phthalocyanine Pc 4 in a Rabbit Model—A Pilot Study
Objective: The silicon phthalocyanine Pc 4 is a photosensitizing agent previously shown to be a promising treatment for cutaneous neoplasms using photodynamic therapy (PDT). Based on prior preclinical studies, we believe Pc 4‐PDT has potential as a targeted treatment of human recurrent respiratory papillomatosis or laryngeal leukoplakia by direct injection into mucosal surfaces.Methods: This was a proof‐of‐concept pilot study assessing direct mucosal injection of Pc 4 into buccal and vocal fold mucosae in a rabbit model. Five New Zealand white rabbits underwent tattooing of bilateral buccal mucosae to delineate injection sites, followed by submucosal injections of control and Pc 4 solutions. Rabbits were monitored for post‐injection tolerance. Punch biopsies were obtained from injected mucosa and assessed histopathologically. Once the buccal mucosa was found to be tolerant, vocal folds of three rabbits were injected. The rabbits were then sacrificed, and laryngeal tissue was assessed histopathologically.Results: All rabbits tolerated injection of Pc 4 and control solutions into buccal mucosa with no evidence of gross visual inflammatory changes and no changes in behavior or masticatory function. Histopathologic analysis of Pc 4 injected buccal and control mucosal tissue revealed mild focal histological changes and no stigmata of diffuse inflammatory reactions. The histopathologic analysis of Pc 4 injected into laryngeal tissue revealed similar findings with addition of mild eosinophilia in one sample.Conclusion: Direct mucosal injection of Pc 4 in rabbit buccal and vocal fold mucosae appears to be well tolerated with no gross inflammatory changes, and only mild histopathologic inflammatory changes observed.Level of Evidence: NA Laryngoscope, 2024
- 22 September 2023
- Published by Wiley in The Laryngoscope
- Vol. 134 (3) , 1147-1154
The Development of Head and Neck Cancer in Patients with the Isolated Complaint of Globus Pharyngeus
Objectives: Globus pharyngeus (GP) is a perplexing problem that accounts for 4% of referrals to otolaryngologists. Workup can be extensive and may not be definitive in terms of etiology. The concern that lingers is that of a subtle cancer, which can prolong anxiety and increase testing cost. The aim of this study was to identify the incidence of head and neck cancer (HNC) in patients diagnosed with GP.Methods: Longitudinal data were captured from two academic institutions, identifying patients with a new diagnosis of globus pharyngeus in 2015. The patient cohort was tracked for at least 4 years to assure follow‐up and ability to determine if a HNC developed. Additional demographic data was also collected to determine most common consults, treatments, and testing employed.Results: Excluding patients with previous diagnosis of HNC, 377 patients were identified who presented with GP in 2015 that had at least 4 years of follow‐up. Demographics were predominantly women (64.65%), with a mean age of 56.48 years at diagnosis, and the most common provider specialty on the first visit was otolaryngology (39.52%). Four patients ultimately developed HN cancer, for an overall incidence of 1% for the 4‐year period of 2015–2019.Conclusions: Given the long‐term follow‐up of this population, the overall incidence of developing a head and neck cancer, with a presenting symptom of globus, is low. This is the largest study to date to report the percentage of patients endorsing GP to then subsequently develop HNC. This helps otolaryngologists to reassure patients who have a normal comprehensive exam, flexible endoscopy, and targeted studies.Level of Evidence: 4 Laryngoscope, 134:1147–1154, 2024
- 22 September 2023
- Published by Wiley in The Laryngoscope
- Vol. 134 (3) , 1147-1154
The Development of Head and Neck Cancer in Patients with the Isolated Complaint of Globus Pharyngeus
Objectives: Globus pharyngeus (GP) is a perplexing problem that accounts for 4% of referrals to otolaryngologists. Workup can be extensive and may not be definitive in terms of etiology. The concern that lingers is that of a subtle cancer, which can prolong anxiety and increase testing cost. The aim of this study was to identify the incidence of head and neck cancer (HNC) in patients diagnosed with GP.Methods: Longitudinal data were captured from two academic institutions, identifying patients with a new diagnosis of globus pharyngeus in 2015. The patient cohort was tracked for at least 4 years to assure follow‐up and ability to determine if a HNC developed. Additional demographic data was also collected to determine most common consults, treatments, and testing employed.Results: Excluding patients with previous diagnosis of HNC, 377 patients were identified who presented with GP in 2015 that had at least 4 years of follow‐up. Demographics were predominantly women (64.65%), with a mean age of 56.48 years at diagnosis, and the most common provider specialty on the first visit was otolaryngology (39.52%). Four patients ultimately developed HN cancer, for an overall incidence of 1% for the 4‐year period of 2015–2019.Conclusions: Given the long‐term follow‐up of this population, the overall incidence of developing a head and neck cancer, with a presenting symptom of globus, is low. This is the largest study to date to report the percentage of patients endorsing GP to then subsequently develop HNC. This helps otolaryngologists to reassure patients who have a normal comprehensive exam, flexible endoscopy, and targeted studies.Level of Evidence: 4 Laryngoscope, 134:1147–1154, 2024
- Open Access
- 1 November 2021
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 8 (11) , e00656
Unusual Location of an Unusual Malignancy
- 1 November 2021
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 8 (11) , e00656
Open AccessUnusual Location of an Unusual Malignancy
- 18 October 2021
- Published by Wiley in The Laryngoscope
- Vol. 132 (7) , 1388-1402
The Utility of Comorbidity Indices in Assessing Head and Neck Surgery Outcomes: A Systematic Review
Objective: To evaluate the utility of comorbidity index (CI) scores in predicting outcomes in head and neck surgery (HNS). The CIs evaluated were the Charlson Comorbidity Index (CCI), Elixhauser Comorbidity Index (ECI), Kaplan‐Feinstein Index (KFI), American Society of Anesthesiologists Physical Status (ASA‐PS), Adult Comorbidity Evaluation‐27 (ACE‐27), National Cancer Institute Comorbidity Index (NCI‐CI), and the Washington University Head and Neck Comorbidity Index (WUHNCI).Methods: We report a systematic review according to the 2009 Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines. Electronic databases (PubMed, Cochrane, and Embase) and manual search of bibliographies identified manuscripts addressing how CI scores related to HNS outcomes.Results: A total of 116 studies associated CI scores with HNS outcomes. CIs were represented in the literature as follows: ASA‐PS (70/116), CCI (39/116), ACE‐27 (24/116), KFI (7/116), NCI‐CI (3/116), ECI (2/116), and WUHNCI (1/116). The most frequently cited justification for calculating each CI (if provided) was: CCI for its validation in other studies, ACE‐27 for its utility in cancer patients, and ECI for its comprehensive design. In general, the CCI and ACE‐27 were predictive of mortality in HNS. The ECI was most consistent in predicting >1‐year mortality. The ACE‐27 and KFI were most consistent in predicting medical complications.Conclusion: Despite inconsistencies in the literature, CIs provide insights into the impact of comorbidities on outcomes in HNS. These scores should be employed as an adjunct in the preoperative assessment of HNS patients. Comparative studies are needed to identify indices that are most reliable in predicting HNS outcomes.Level of Evidence: NA Laryngoscope, 132:1388–1402, 2022
- 18 October 2021
- Published by Wiley in The Laryngoscope
- Vol. 132 (7) , 1388-1402
The Utility of Comorbidity Indices in Assessing Head and Neck Surgery Outcomes: A Systematic Review
Objective: To evaluate the utility of comorbidity index (CI) scores in predicting outcomes in head and neck surgery (HNS). The CIs evaluated were the Charlson Comorbidity Index (CCI), Elixhauser Comorbidity Index (ECI), Kaplan‐Feinstein Index (KFI), American Society of Anesthesiologists Physical Status (ASA‐PS), Adult Comorbidity Evaluation‐27 (ACE‐27), National Cancer Institute Comorbidity Index (NCI‐CI), and the Washington University Head and Neck Comorbidity Index (WUHNCI).Methods: We report a systematic review according to the 2009 Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines. Electronic databases (PubMed, Cochrane, and Embase) and manual search of bibliographies identified manuscripts addressing how CI scores related to HNS outcomes.Results: A total of 116 studies associated CI scores with HNS outcomes. CIs were represented in the literature as follows: ASA‐PS (70/116), CCI (39/116), ACE‐27 (24/116), KFI (7/116), NCI‐CI (3/116), ECI (2/116), and WUHNCI (1/116). The most frequently cited justification for calculating each CI (if provided) was: CCI for its validation in other studies, ACE‐27 for its utility in cancer patients, and ECI for its comprehensive design. In general, the CCI and ACE‐27 were predictive of mortality in HNS. The ECI was most consistent in predicting >1‐year mortality. The ACE‐27 and KFI were most consistent in predicting medical complications.Conclusion: Despite inconsistencies in the literature, CIs provide insights into the impact of comorbidities on outcomes in HNS. These scores should be employed as an adjunct in the preoperative assessment of HNS patients. Comparative studies are needed to identify indices that are most reliable in predicting HNS outcomes.Level of Evidence: NA Laryngoscope, 132:1388–1402, 2022
- 27 January 2021
- Published by Wiley in The Laryngoscope
- Vol. 131 (12) , 2666-2670
Dysphagia Evaluation: The Added Value of Concurrent MBS and Esophagram
Objectives/Hypothesis: Dysphagia is associated with increased mortality and healthcare costs. The modified barium swallow study (MBS) is the gold standard in assessing oropharyngeal dysphagia, but does not evaluate the esophagus. A barium esophagram can visualize the esophagus but does not evaluate the oropharyngeal swallow, nor does it utilize the expertise of speech and language pathologists. Providers may order one or both studies yet still risk missing critical pathology.Study Design: Retrospective cohort study.Methods: A retrospective chart review was conducted at an academic medical center between January 2016 and June 2019 focused on patients who had both MBS and esophagram as imaging for dysphagia evaluation. Analysis determined whether MBS and esophagram performed concomitantly improved diagnostic clarity.Results: A total of 5,183 patients underwent 6,066 swallow studies for dysphagia in the study period. Of which, 124 of these patients had concurrent MBS and esophagram. 10.5% of concurrent studies demonstrated a congruent negative evaluation. 59.7% of patients had an unremarkable MBS or esophagram paired with abnormal findings within the corresponding esophagram or MBS, respectively. 29.8% had both MBS and esophagrams that demonstrated an abnormality, but with unique pathologies identified by each study. In total, 85.1% of unremarkable MBS or esophagrams were paired with abnormal findings in the corresponding esophagram or MBS, respectively.Conclusion: Selection of diagnostic testing is variable among providers and may be influenced by healthcare systems. This analysis revealed that MBS and esophagrams provide unique diagnoses. Concurrent MBS and esophagrams may improve diagnostic accuracy, yet minimize additional studies. National practices around dysphagia diagnostics are inconsistent and would benefit from standardization.Level of Evidence: 4 Laryngoscope, 131:2666–2670, 2021
- 27 January 2021
- Published by Wiley in The Laryngoscope
- Vol. 131 (12) , 2666-2670
Dysphagia Evaluation: The Added Value of Concurrent MBS and Esophagram
Objectives/Hypothesis: Dysphagia is associated with increased mortality and healthcare costs. The modified barium swallow study (MBS) is the gold standard in assessing oropharyngeal dysphagia, but does not evaluate the esophagus. A barium esophagram can visualize the esophagus but does not evaluate the oropharyngeal swallow, nor does it utilize the expertise of speech and language pathologists. Providers may order one or both studies yet still risk missing critical pathology.Study Design: Retrospective cohort study.Methods: A retrospective chart review was conducted at an academic medical center between January 2016 and June 2019 focused on patients who had both MBS and esophagram as imaging for dysphagia evaluation. Analysis determined whether MBS and esophagram performed concomitantly improved diagnostic clarity.Results: A total of 5,183 patients underwent 6,066 swallow studies for dysphagia in the study period. Of which, 124 of these patients had concurrent MBS and esophagram. 10.5% of concurrent studies demonstrated a congruent negative evaluation. 59.7% of patients had an unremarkable MBS or esophagram paired with abnormal findings within the corresponding esophagram or MBS, respectively. 29.8% had both MBS and esophagrams that demonstrated an abnormality, but with unique pathologies identified by each study. In total, 85.1% of unremarkable MBS or esophagrams were paired with abnormal findings in the corresponding esophagram or MBS, respectively.Conclusion: Selection of diagnostic testing is variable among providers and may be influenced by healthcare systems. This analysis revealed that MBS and esophagrams provide unique diagnoses. Concurrent MBS and esophagrams may improve diagnostic accuracy, yet minimize additional studies. National practices around dysphagia diagnostics are inconsistent and would benefit from standardization.Level of Evidence: 4 Laryngoscope, 131:2666–2670, 2021
- 8 May 2020
- Published by Wiley in The Laryngoscope
- Vol. 131 (1) , E76-E82
Discharge by Noon: A Checklist Initiative by the Otolaryngology Service
Objectives/Hypothesis: Hospital length of stay (LOS) and throughput are critical issues for hospitals. Late hospital discharges contribute to bottlenecks in the emergency department, overcrowd surgical and procedural areas, and limit patient tertiary‐care center transfers. Our goal was to increase discharge by noon (DCBN) percentage from 8% to over 50% in a sustainable manner.Study Design: Retrospective Review.Methods: We used a multiple time series design and a quality improvement approach. An interdisciplinary improvement team (IIT) identified the main causes contributing to late discharge and then developed and implemented multiple interventions to increase the percentage of DCBN. Admissions and discharge information were obtained for all patients in the otolaryngology service (January 2014–September 2017). The intervention was implemented in July 2015. The primary outcome was the percentage of DCBN per month. Secondary outcomes were LOS, case‐mix index (CMI), patient experience, and 30‐day readmissions. We analyzed the impact of our intervention and outcomes at the preintervention, peri‐intervention, and postintervention periods.Results: One thousand four hundred sixty‐four admissions to the otolaryngology service were included. Throughout the intervention period, the percentage of patients DCBN increased. Analysis of the intervention showed significant DCBN change of 15% in the first versus 42% in the last 12‐months (P < .001), and shorter LOS (−1.4 days, P < .001) and lower CMI (−0.6, P < .001) in the DCBN group. Patient satisfaction scores improved by 4% (P < .05), and no difference in 30‐day readmission rates (P = .29) was shown.Conclusions: This multifaceted intervention improved early discharge and patient experience. Our checklist of key behaviors could be applied throughout other services and hospitals with reproducible success.Level of Evidence: 4 Laryngoscope, 131:E76–E82, 2021
- 8 May 2020
- Published by Wiley in The Laryngoscope
- Vol. 131 (1) , E76-E82
Discharge by Noon: A Checklist Initiative by the Otolaryngology Service
Objectives/Hypothesis: Hospital length of stay (LOS) and throughput are critical issues for hospitals. Late hospital discharges contribute to bottlenecks in the emergency department, overcrowd surgical and procedural areas, and limit patient tertiary‐care center transfers. Our goal was to increase discharge by noon (DCBN) percentage from 8% to over 50% in a sustainable manner.Study Design: Retrospective Review.Methods: We used a multiple time series design and a quality improvement approach. An interdisciplinary improvement team (IIT) identified the main causes contributing to late discharge and then developed and implemented multiple interventions to increase the percentage of DCBN. Admissions and discharge information were obtained for all patients in the otolaryngology service (January 2014–September 2017). The intervention was implemented in July 2015. The primary outcome was the percentage of DCBN per month. Secondary outcomes were LOS, case‐mix index (CMI), patient experience, and 30‐day readmissions. We analyzed the impact of our intervention and outcomes at the preintervention, peri‐intervention, and postintervention periods.Results: One thousand four hundred sixty‐four admissions to the otolaryngology service were included. Throughout the intervention period, the percentage of patients DCBN increased. Analysis of the intervention showed significant DCBN change of 15% in the first versus 42% in the last 12‐months (P < .001), and shorter LOS (−1.4 days, P < .001) and lower CMI (−0.6, P < .001) in the DCBN group. Patient satisfaction scores improved by 4% (P < .05), and no difference in 30‐day readmission rates (P = .29) was shown.Conclusions: This multifaceted intervention improved early discharge and patient experience. Our checklist of key behaviors could be applied throughout other services and hospitals with reproducible success.Level of Evidence: 4 Laryngoscope, 131:E76–E82, 2021
- 1 January 2019
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 40 (1) , 74-77
Multi-specialty knowledge on surgical a management: Implementation of an educational initiative
- 1 January 2019
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 40 (1) , 74-77
Multi-specialty knowledge on surgical a management: Implementation of an educational initiative
- 2 August 2012
- Published by Wiley in The Laryngoscope
- Vol. 122 (10) , 2234-2239
Hunsaker mon‐jet tube ventilation: A 15‐year experience
Objective/Hypothesis: The Hunsaker Mon‐Jet tube (HMJT) (Xomed, Jacksonville, FL) has been used effectively for subglottic ventilation. We previously reported a series of 552 patients over a 10‐year period with no major complications. This is a continuation of that series with an additional 5 years of cases.Study Design: Retrospective consecutive case series.Methods: Patients who were ventilated with the HMJT for microlaryngeal surgery at the University of Washington Medical Center over a 15‐year period (1995–2010) were identified from the Voice Disorders database. Charts were reviewed for demographic data, laryngeal diagnosis, and anesthetic parameters. Main outcome measure was the rate of complications.Results: Fifty‐seven complications occurred in 49 cases out of 839 cases (5.8% complication rate). In descending order, the complications were hypoxia (SpO2 60 mm Hg, n = 17, 2.0%), airway obstruction (n = 4, 0.5%), barotrauma (n = 2, 0.2%), seeding of blood into trachea (n = 2, 0.2%), submucosal injection of air (n = 1, 0.1%), and mucosal damage (n = 1, 0.1%). Factors associated with complications included high body mass index (P = .04), American Society of Anesthesiology class III or IV (P = .01), history of heart disease (P = .02), history of previous laryngeal surgery (P = .02), longer duration of case (P = .006), and laser use (P = .005).Conclusions: Although subglottic ventilation via an HMJT is a safe alternative to traditional endotracheal intubation in an appropriately selected population, practitioners should remain vigilant about the known complications. Laryngoscope, 2012
- 2 August 2012
- Published by Wiley in The Laryngoscope
- Vol. 122 (10) , 2234-2239
Hunsaker mon‐jet tube ventilation: A 15‐year experience
Objective/Hypothesis: The Hunsaker Mon‐Jet tube (HMJT) (Xomed, Jacksonville, FL) has been used effectively for subglottic ventilation. We previously reported a series of 552 patients over a 10‐year period with no major complications. This is a continuation of that series with an additional 5 years of cases.Study Design: Retrospective consecutive case series.Methods: Patients who were ventilated with the HMJT for microlaryngeal surgery at the University of Washington Medical Center over a 15‐year period (1995–2010) were identified from the Voice Disorders database. Charts were reviewed for demographic data, laryngeal diagnosis, and anesthetic parameters. Main outcome measure was the rate of complications.Results: Fifty‐seven complications occurred in 49 cases out of 839 cases (5.8% complication rate). In descending order, the complications were hypoxia (SpO2 60 mm Hg, n = 17, 2.0%), airway obstruction (n = 4, 0.5%), barotrauma (n = 2, 0.2%), seeding of blood into trachea (n = 2, 0.2%), submucosal injection of air (n = 1, 0.1%), and mucosal damage (n = 1, 0.1%). Factors associated with complications included high body mass index (P = .04), American Society of Anesthesiology class III or IV (P = .01), history of heart disease (P = .02), history of previous laryngeal surgery (P = .02), longer duration of case (P = .006), and laser use (P = .005).Conclusions: Although subglottic ventilation via an HMJT is a safe alternative to traditional endotracheal intubation in an appropriately selected population, practitioners should remain vigilant about the known complications. Laryngoscope, 2012